Squamous Cell Carcinoma (SCC) and Adenocarcinoma (AD) Differentiation in Non-Small Cell Lung Cancer (NSCLC) using New miRNA Biomarker Panel
Ready-to-Use fully optimized SSNA miRNA In Situ Hybridization (ISH) Kit
Lung cancer represents a heterogeneous group of tumors comprised of mostly squamous cell carcinomas (SCC) and adenocarcinomas (AD). These tumors can be challenging to classify due to heterogeneity, sampling and lack of differentiation. Targeted molecular therapies for lung cancer treatment require accurate classification for optimal response. microRNAs (miRNAs) are a group of small, endogenous, noncoding RNAs with critical functions on gene regulation. Their expression profiles have great potential in tumor diagnosis and prognosis since they play essential roles in tissue differentiation during normal development and oncogenesis. Dysregulation of miRNA expression has been reported in different cancer types including lung cancer. In the era of precision medicine, it is essential to identify the novel diagnostic biomarkers for better management of lung cancer and increased patient care.
Super Sensitive Nucleic Acid (SSNA) miRNA probes:
BioGenex has developed proprietary Super Sensitive Nucleic Acid (SSNA) miRNA probes that enhance signals from intrinsically low populated miRNAs. The SSNA oligos are synthesized using specially designed bases to give super high melting temperatures. The high melting temperatures enable stringent washes at elevated temperatures to remove non-specific binding. BioGenex miRNA probes are dual-end labeled on 3’ and 5’ with five FAM molecules that amplify the signal, giving intense stains. The high-density fluorophore-labeled SSNA probes combined with the BioGenex Super Sensitive ™ Detection System aid in studying the lowly expressed miRNA populations and miRNA expression profiles to assess the physiological function of miRNA.
The miRNA expression profiles are used to assess the cancer type or conditions for the below types:
- Cancer of unknown primary
- Undifferentiated and poorly differentiated tumors
- Classification of cancer subtypes
- Grading and staging of cancer
BioGenex is pleased to launch three Super Sensitive Nucleic Acid microRNA in situ hybridization (SSNA miRNA ISH) probes and automated systems for differentiation of SCC and AD. BioGenex SSNA miRNA ISH probes give consistent, reproducible and reliable outcomes. Adaptation of automated processing using Xmatrx® in ISH procedure eliminates error-prone manual steps and greatly increases reproducibility, accuracy and sensitivity of the test results.
BioGenex miRNA ISH detection provides visualization of miRNA in a histological context, which is helpful in determining tumor cell-type specific expression. miRNA expression profile was evaluated in formalin-fixed paraffin-embedded (FFPE) lung cancers consisting of SCC and AD, paired lymph node metastasis and normal lung tissue. miRNA-205 and miR-196a were strongly upregulated in SCC, while miR-375 was downregulated in SCC and invasive lymph node metastasis, indicating a potential diagnostic utility of these miRNAs in the differentiation of SCC and AD.
Please click on above links to download Biomarker Panel and Application Note for Differentiation of Squamous Cell Carcinoma and Adenocarcinoma
BioGenex also has an extensive catalog of over 240 unique miRNA probes